These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18006097)

  • 21. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
    Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
    Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
    Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
    Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
    Martinez-Balibrea E; Abad A; Aranda E; Sastre J; Manzano JL; Díaz-Rubio E; Gómez-España A; Aparicio J; García T; Maestu I; Martínez-Cardús A; Ginés A; Guino E;
    Eur J Cancer; 2008 Jun; 44(9):1229-37. PubMed ID: 18448328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indole-3-carbinol enhances anti-proliferative, but not anti-invasive effects of oxaliplatin in colorectal cancer cell lines.
    Howells LM; Neal CP; Brown MC; Berry DP; Manson MM
    Biochem Pharmacol; 2008 May; 75(9):1774-82. PubMed ID: 18358454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The magnitude and time-dependence of the apoptotic response of normal and malignant cells subjected to ionizing radiation versus hyperthermia.
    Vorotnikova E; Ivkov R; Foreman A; Tries M; Braunhut SJ
    Int J Radiat Biol; 2006 Aug; 82(8):549-59. PubMed ID: 16966182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model.
    Tippayamontri T; Kotb R; Paquette B; Sanche L
    Anticancer Res; 2012 Oct; 32(10):4395-404. PubMed ID: 23060564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
    Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
    Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silencing of CD59 enhanced the sensitivity of HT29 cells to 5-Fluorouracil and Oxaliplatin.
    Yin H; Li C; Wang S; Guo Q; Ren X; Jiang G
    J Infect Chemother; 2015 Jan; 21(1):8-15. PubMed ID: 25444672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
    Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiproliferative and antimetastatic effects of the ethanolic extract of Phellinus igniarius (Linnearus: Fries) Quelet.
    Song TY; Lin HC; Yang NC; Hu ML
    J Ethnopharmacol; 2008 Jan; 115(1):50-6. PubMed ID: 17936529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.
    Seierstad T; Folkvord S; Røe K; Flatmark K; Skretting A; Olsen DR
    Neoplasia; 2007 May; 9(5):392-400. PubMed ID: 17534444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition.
    Richard SM; Martinez Marignac VL
    J Cancer Res Ther; 2015; 11(2):336-40. PubMed ID: 26148596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.
    Pauwels B; Wouters A; Peeters M; Vermorken JB; Lardon F
    Future Oncol; 2010 Sep; 6(9):1485-96. PubMed ID: 20919831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
    Lim T; Lee I; Kim J; Kang WK
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):316-25. PubMed ID: 26277021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
    Saelen MG; Ree AH; Kristian A; Fleten KG; Furre T; Hektoen HH; Flatmark K
    Radiat Oncol; 2012 Sep; 7():165. PubMed ID: 23017053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
    He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
    Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.